📋 Quick Summary
How to build a PCCP FDA will approve for AI/ML-based medical devices. What your change scope, performance bounds, and monitoring plan must specify.
📬 Get daily updates like this in your inbox. Subscribe to RegWatch Daily →
What a PCCP Enables
FDA's Predetermined Change Control Plan guidance, finalized in 2023, gives AI/ML device manufacturers a mechanism to update their algorithm after initial clearance without filing a new 510(k) for every modification. The PCCP pre-authorizes a defined set of future changes at the time of initial clearance.
Without a PCCP, every algorithm improvement is a potential 510(k) or De Novo. Manufacturers who cleared AI/ML devices without one often spend twelve to eighteen months in regulatory review for each model update. The PCCP breaks that cycle.
What FDA Requires in a PCCP
A PCCP must specify three things with precision. First, the modification protocol: exactly what types of changes are covered, described with enough specificity that FDA can evaluate whether a proposed future change falls within scope. Second, the performance bounds: quantitative thresholds that define the limits of pre-authorized performance. Third, the methodology for verifying that a change stays within authorized bounds before deployment.
Vague PCCPs get rejected or stripped to nothing during review. If your modification protocol says the algorithm may be retrained on new data, FDA will ask what data, what volume, what labeling methodology, and what retraining procedure.
Common PCCP Rejection Reasons
The most common reason FDA rejects or restricts a PCCP is insufficient specificity in the modification protocol. Statements like the model may be updated to improve performance are not acceptable. You need to define the change type (retraining, fine-tuning, architecture change), the trigger conditions, the data requirements, and the validation methodology.
Performance bounds are the second frequent failure point. Bounds must be expressed as quantitative metrics that FDA can evaluate. If your device claims sensitivity of ninety percent, your PCCP bound might specify that post-modification sensitivity must remain within two percentage points of the cleared device performance on a defined holdout set.
Get this intelligence in your inbox every morning.
Daily regulatory briefings for QA managers, SaMD teams, and startup RA leads — personalized, actionable, free.
Subscribe Free →Free forever. Unsubscribe anytime.
Build Your PCCP Before Initial Clearance
The optimal time to design your PCCP is before your initial 510(k) or De Novo submission, not after clearance. FDA reviews the PCCP as part of the initial submission. Building it in from the start means your development process, data governance, and validation methodology are designed to support the PCCP from day one.
Your pre-submission meeting for an AI/ML device should include PCCP strategy as a primary agenda item. Bring your proposed modification protocol and performance bounds structure. FDA's Digital Health Center of Excellence reviews these before you finalize your submission.
📚 Sources & References
Get this intelligence in your inbox every morning.
Daily regulatory briefings for QA managers, SaMD teams, and startup RA leads — personalized, actionable, free.
Subscribe Free →Free forever. Unsubscribe anytime.
Get the SaMD Regulatory Toolkit — includes PCCP template and AI/ML validation framework for 510(k) preparation.
Get the SaMD & Software Compliance Bundle — $347